{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Inducteurs du cytochrome P-450 CYP2C9 : Questions médicales les plus fréquentes",
"headline": "Inducteurs du cytochrome P-450 CYP2C9 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Inducteurs du cytochrome P-450 CYP2C9 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-07",
"dateModified": "2025-04-01",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Inducteurs du cytochrome P-450 CYP2C9"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Inducteurs des enzymes du cytochrome P-450",
"url": "https://questionsmedicales.fr/mesh/D065693",
"about": {
"@type": "MedicalCondition",
"name": "Inducteurs des enzymes du cytochrome P-450",
"code": {
"@type": "MedicalCode",
"code": "D065693",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.349"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Inducteurs du cytochrome P-450 CYP2C9",
"alternateName": "Cytochrome P-450 CYP2C9 Inducers",
"code": {
"@type": "MedicalCode",
"code": "D065698",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Miklós Poór",
"url": "https://questionsmedicales.fr/author/Mikl%C3%B3s%20Po%C3%B3r",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, Pécs H-7624, Hungary; Lab-on-a-Chip Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary. Electronic address: poor.miklos@pte.hu."
}
},
{
"@type": "Person",
"name": "Jian-Ping Cai",
"url": "https://questionsmedicales.fr/author/Jian-Ping%20Cai",
"affiliation": {
"@type": "Organization",
"name": "The Key laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China."
}
},
{
"@type": "Person",
"name": "Slávka Bodnárová",
"url": "https://questionsmedicales.fr/author/Sl%C3%A1vka%20Bodn%C3%A1rov%C3%A1",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, Pécs H-7624, Hungary; Lab-on-a-Chip Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary."
}
},
{
"@type": "Person",
"name": "Eszter Fliszár-Nyúl",
"url": "https://questionsmedicales.fr/author/Eszter%20Flisz%C3%A1r-Ny%C3%BAl",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, Pécs H-7624, Hungary; Lab-on-a-Chip Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary."
}
},
{
"@type": "Person",
"name": "Jian Liu",
"url": "https://questionsmedicales.fr/author/Jian%20Liu",
"affiliation": {
"@type": "Organization",
"name": "The Key laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Pulse Wave Analysis in Obese Children with and without Metabolic Syndrome",
"datePublished": "2023-07-20",
"url": "https://questionsmedicales.fr/article/37470253",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.4274/jcrpe.galenos.2023.2022-10-21"
}
},
{
"@type": "ScholarlyArticle",
"name": "Feasibility of Brachial Occlusion Technique for Beat-to-Beat Pulse Wave Analysis.",
"datePublished": "2022-09-26",
"url": "https://questionsmedicales.fr/article/36236381",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/s22197285"
}
},
{
"@type": "ScholarlyArticle",
"name": "Oscillometric pulse wave analysis for detecting low flow arteriovenous fistula.",
"datePublished": "2023-06-24",
"url": "https://questionsmedicales.fr/article/37355570",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12882-023-03243-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pulse Wave Analysis Method of Cardiovascular Parameters Extraction for Health Monitoring.",
"datePublished": "2023-01-31",
"url": "https://questionsmedicales.fr/article/36767962",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijerph20032597"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pulse Wave Velocity and Sarcopenia in Older Persons-A Systematic Review and Meta-Analysis.",
"datePublished": "2022-05-26",
"url": "https://questionsmedicales.fr/article/35682063",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijerph19116477"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Mécanismes moléculaires de l'action pharmacologique",
"item": "https://questionsmedicales.fr/mesh/D045504"
},
{
"@type": "ListItem",
"position": 5,
"name": "Inducteurs des enzymes du cytochrome P-450",
"item": "https://questionsmedicales.fr/mesh/D065693"
},
{
"@type": "ListItem",
"position": 6,
"name": "Inducteurs du cytochrome P-450 CYP2C9",
"item": "https://questionsmedicales.fr/mesh/D065698"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Inducteurs du cytochrome P-450 CYP2C9 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Comment identifier un inducteur du CYP2C9 ?\nQuels tests sont utilisés pour évaluer l'activité du CYP2C9 ?\nQuels signes indiquent une induction du CYP2C9 ?\nComment les interactions médicamenteuses sont-elles diagnostiquées ?\nQuels médicaments sont souvent des inducteurs du CYP2C9 ?",
"url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Pulse+Wave+Analysis#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Quels symptômes peuvent indiquer une induction du CYP2C9 ?\nComment l'induction du CYP2C9 affecte-t-elle les médicaments ?\nQuels effets secondaires peuvent survenir ?\nLes symptômes varient-ils selon les patients ?\nQuels signes cliniques sont observés ?",
"url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Pulse+Wave+Analysis#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Comment prévenir l'induction du CYP2C9 ?\nLes patients doivent-ils informer leur médecin des médicaments ?\nDes tests génétiques peuvent-ils aider à la prévention ?\nComment éduquer les patients sur les inducteurs ?\nLes changements de mode de vie peuvent-ils aider ?",
"url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Pulse+Wave+Analysis#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Comment ajuster le traitement en cas d'induction du CYP2C9 ?\nQuels médicaments peuvent être utilisés pour contrer l'induction ?\nComment surveiller l'efficacité du traitement ?\nQuels sont les risques d'un traitement inapproprié ?\nLes changements de traitement doivent-ils être rapides ?",
"url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Pulse+Wave+Analysis#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Quelles complications peuvent résulter de l'induction du CYP2C9 ?\nComment l'induction affecte-t-elle la santé globale ?\nLes complications sont-elles réversibles ?\nQuels sont les risques à long terme ?\nComment gérer les complications liées à l'induction ?",
"url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Pulse+Wave+Analysis#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Inducteurs du cytochrome P-450 CYP2C9",
"description": "Quels sont les principaux facteurs de risque d'induction ?\nLa génétique joue-t-elle un rôle dans l'induction ?\nLes habitudes alimentaires influencent-elles l'induction ?\nLes maladies hépatiques augmentent-elles le risque ?\nLes interactions médicamenteuses sont-elles un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D065698?mesh_terms=Pulse+Wave+Analysis#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier un inducteur du CYP2C9 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'identification se fait par l'analyse des antécédents médicamenteux et des tests de métabolisme."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité du CYP2C9 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de pharmacogénétique et des dosages de médicaments peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une induction du CYP2C9 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une diminution de l'efficacité des médicaments métabolisés par CYP2C9 peut être un signe."
}
},
{
"@type": "Question",
"name": "Comment les interactions médicamenteuses sont-elles diagnostiquées ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont diagnostiquées par l'examen des interactions dans les bases de données médicales."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont souvent des inducteurs du CYP2C9 ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme la rifampicine et certains anticonvulsivants sont des inducteurs."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer une induction du CYP2C9 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes de sous-dosage des médicaments, comme une douleur persistante, peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Comment l'induction du CYP2C9 affecte-t-elle les médicaments ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut réduire l'efficacité des médicaments, entraînant des symptômes de la maladie sous-jacente."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires peuvent survenir ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets secondaires liés à un sous-dosage, comme des convulsions, peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon les patients ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de la génétique et des médicaments pris."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont observés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes cliniques comme une réponse insuffisante au traitement peuvent être observés."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'induction du CYP2C9 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les inducteurs connus et surveiller les interactions médicamenteuses est essentiel."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils informer leur médecin des médicaments ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, informer le médecin de tous les médicaments pris aide à prévenir les interactions."
}
},
{
"@type": "Question",
"name": "Des tests génétiques peuvent-ils aider à la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests génétiques peuvent identifier les patients à risque d'induction enzymatique."
}
},
{
"@type": "Question",
"name": "Comment éduquer les patients sur les inducteurs ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'éducation sur les médicaments inducteurs et leurs effets est cruciale pour la prévention."
}
},
{
"@type": "Question",
"name": "Les changements de mode de vie peuvent-ils aider ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des changements de mode de vie, comme une alimentation saine, peuvent aider."
}
},
{
"@type": "Question",
"name": "Comment ajuster le traitement en cas d'induction du CYP2C9 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut être nécessaire d'augmenter la dose des médicaments affectés pour compenser."
}
},
{
"@type": "Question",
"name": "Quels médicaments peuvent être utilisés pour contrer l'induction ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs du CYP2C9 peuvent être utilisés pour réduire l'induction enzymatique."
}
},
{
"@type": "Question",
"name": "Comment surveiller l'efficacité du traitement ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La surveillance se fait par des tests réguliers des niveaux de médicaments dans le sang."
}
},
{
"@type": "Question",
"name": "Quels sont les risques d'un traitement inapproprié ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un traitement inapproprié peut entraîner des complications graves, comme des crises épileptiques."
}
},
{
"@type": "Question",
"name": "Les changements de traitement doivent-ils être rapides ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les changements doivent être faits prudemment pour éviter des effets indésirables."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent résulter de l'induction du CYP2C9 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des crises convulsives ou une résistance au traitement peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment l'induction affecte-t-elle la santé globale ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut compromettre la santé en rendant les traitements moins efficaces, aggravant les maladies."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un ajustement approprié du traitement."
}
},
{
"@type": "Question",
"name": "Quels sont les risques à long terme ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques à long terme incluent des maladies chroniques dues à un traitement inefficace."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées à l'induction ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique un suivi régulier et des ajustements de traitement basés sur les symptômes."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque d'induction ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'utilisation de certains médicaments, l'alcool et des maladies hépatiques."
}
},
{
"@type": "Question",
"name": "La génétique joue-t-elle un rôle dans l'induction ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des variations génétiques peuvent influencer l'activité du CYP2C9 et son induction."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles l'induction ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines habitudes alimentaires, comme la consommation de pamplemousse, peuvent influencer l'induction."
}
},
{
"@type": "Question",
"name": "Les maladies hépatiques augmentent-elles le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les maladies hépatiques peuvent augmenter le risque d'induction du CYP2C9."
}
},
{
"@type": "Question",
"name": "Les interactions médicamenteuses sont-elles un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les interactions entre médicaments peuvent augmenter le risque d'induction enzymatique."
}
}
]
}
]
}
Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, Pécs H-7624, Hungary; Lab-on-a-Chip Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary. Electronic address: poor.miklos@pte.hu.
Publications dans "Inducteurs du cytochrome P-450 CYP2C9" :
The Key laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China.
Publications dans "Inducteurs du cytochrome P-450 CYP2C9" :
Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, Pécs H-7624, Hungary; Lab-on-a-Chip Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary.
Publications dans "Inducteurs du cytochrome P-450 CYP2C9" :
Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Rókus u. 2, Pécs H-7624, Hungary; Lab-on-a-Chip Research Group, János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, Pécs H-7624, Hungary.
Publications dans "Inducteurs du cytochrome P-450 CYP2C9" :
The Key laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China.
Publications dans "Inducteurs du cytochrome P-450 CYP2C9" :
Cardiovascular Department, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China.
Publications dans "Inducteurs du cytochrome P-450 CYP2C9" :
Cardiovascular Department, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China.
Publications dans "Inducteurs du cytochrome P-450 CYP2C9" :
Cardiovascular Department, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China.
Publications dans "Inducteurs du cytochrome P-450 CYP2C9" :
The Key laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China.
Publications dans "Inducteurs du cytochrome P-450 CYP2C9" :
To compare pulse wave analysis (PWA) of obese children with and without metabolic syndrome (MS) with healthy, non-obese children and to evaluate the association between PWA findings and additional ris...
From the obese patients examined between June 2019 and June 2021, 41 patients with MS, 36 obese patients without MS, and 34 healthy non-obese children of similar age and gender were evaluated retrospe...
When the three groups were compared, weight standard deviation score (SDS), height SDS and body mass index SDS were all significantly higher in the MS group (p<0.05). The following measurements were s...
Obesity causes higher office, ambulatory and central BP, PWV and LVMI. However our results suggest that additional risk factors associated with MS do not contribute to these parameters, except for 24-...
Czech physiologist Penaz tried to overcome limitations of invasive pulse-contour methods (PCM) in clinical applications by a non-invasive method (finger mounted BP cuff) for continuous arterial wavefo...
Pulse wave analysis may be useful to assess fistula function. We aimed to prospectively evaluate if convenient oscillometric devices are applicable to detect flow below 500 ml/min in a real life clini...
Pulse waves were recorded ambilaterally with the vicorder® device at the brachial artery in 53 patients on haemodialysis with native fistula. Primary variables consisted of the mean slope between the ...
Parameter values above or below the median indicated measurement at the non-fistula side, with sensitivities/specificities of 0.79/0.79 (p < 0.001) for Slope 2, 0.64/0.64 (p = 0.003) for Slope∑ and 0....
Functional surveillance with oscillometry is a promising clinical application to detect a low fistula flow. Among all investigated pulse wave parameters AMP revealed the highest diagnostic accuracy....
A pulse waveform is regarded as an information carrier of the cardiovascular system, which contains multiple interactive cardiovascular parameters reflecting physio-pathological states of bodies. Henc...
The first part of the methodology includes building the sub-pattern libraries and training classifier. This provides a trained classifier and the sub-pattern library with reference pulse waveforms and...
Four hundred and thirty eight (438) randomly selected pulse waveforms were tested to verify the effectiveness of this method. The results show that the classification accuracy is 96.35%. Using statist...
This new method using waveform recognition shows promising results that can directly extract multiple cardiovascular parameters from waveforms with high accuracy. This new approach is efficient and ef...
Sarcopenia and cardiovascular disease share some of the pathophysiologic mechanisms. Sarcopenia is likewise an important feature of frailty and the one potentially related to cardiovascular pathology....
Plaque characterization is essential for stroke prevention. In the study reported herein, we describe a heterogeneous phantom manufacturing technique with varying plaque compositions of different stif...
Five stenotic phantoms (50% stenosis) were fabricated by pouring PVA solutions into 3-D-printed molds. Two of the phantoms had heterogeneous plaque compositions of soft (E...
Arterial phantoms with heterogeneous plaque stiffness were successfully fabricated. Pulse wave velocities of 2.06, 2.21, 2.49, 2.67 and 3.31 m/s were found in the phantom experiments using PWI for hom...
A novel arterial phantom building technique was reported with varying heterogenous plaque compositions of different stiffness. The feasibility of using PWI to evaluate plaque stiffness in stenotic art...
Arterial pulse waves (PWs) such as blood pressure and photoplethysmogram (PPG) signals contain a wealth of information on the cardiovascular (CV) system that can be exploited to assess vascular age an...
We compared cardiovascular parameters obtained with the Mobil-O-Graph and functional capacity assessed by the Duke Activity Status Index (DASI) before and after Heart Transplantation (HT) and also com...
Patients with Polycystic ovary syndrome (PCOS) experienced endocrine disorders that may present vascular function changes. This study aimed to classify and predict PCOS by radial pulse wave parameters...
A case-control study with 459 subjects divided into a PCOS group and a healthy (non-PCOS) group. The pulse wave parameters were measured and analyzed between the two groups. Seven supervised ML classi...
There were 316 subjects in the PCOS group and 143 subjects in the healthy group. Compared to the healthy group, the pulse wave parameters h3/h1 and w/t from both left and right sides were increased wh...
Radial pulse wave signal could identify most PCOS patients accurately (with a good F1 score) and is valuable for early detection and monitoring of PCOS with acceptable overall accuracy. This technique...
Not applicable....
Arterial pulse wave velocity (PWV) is recognized as a convenient method to assess peripheral vascular stiffness. This study explored the clinical characteristics of hand PWV (hPWV) and hand pulse tran...